This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Resumen de acción PRDS
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Competidores de Pardes Biosciences, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.16 |
| 52 Week High | US$3.67 |
| 52 Week Low | US$0.75 |
| Beta | 0.42 |
| 1 Month Change | 2.37% |
| 3 Month Change | 14.29% |
| 1 Year Change | -40.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -79.98% |
Noticias y actualizaciones recientes
We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate
Jul 18
Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation
Jan 20Recent updates
We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate
Jul 18Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation
Jan 20We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully
Oct 01Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19
Sep 13Pardes Biosciences GAAP EPS of -$0.48
Aug 15Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans
Jun 14Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform
Jan 21Rentabilidad de los accionistas
| PRDS | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 0.5% | 3.4% | 1.6% |
| 1Y | -40.0% | 3.8% | 25.1% |
Rentabilidad vs. Industria: PRDS underperformed the US Biotechs industry which returned 7.4% over the past year.
Rentabilidad vs. Mercado: PRDS underperformed the US Market which returned 11.7% over the past year.
Volatilidad de los precios
| PRDS volatility | |
|---|---|
| PRDS Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: PRDS has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: PRDS's weekly volatility has decreased from 12% to 5% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2020 | 57 | Tom Wiggans | www.pardesbio.com |
Resumen de fundamentos de Pardes Biosciences, Inc.
| Estadísticas fundamentales de PRDS | |
|---|---|
| Capitalización bursátil | US$131.19m |
| Beneficios(TTM) | -US$76.14m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-1.7x
Ratio precio-beneficio (PE)¿Está PRDS sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de PRDS | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$76.14m |
| Beneficios | -US$76.14m |
Últimos beneficios comunicados
Jun 30, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.25 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado PRDS a largo plazo?
Ver rendimiento histórico y comparativa